Coordination of glioblastoma cell motility by PKCι.
BACKGROUND
Glioblastoma is one of the deadliest forms of cancer, in part because of its highly invasive nature. The tumor suppressor PTEN is frequently mutated in glioblastoma and is known to contribute to the invasive phenotype. However the downstream events that promote invasion are not fully understood. PTEN loss leads to activation of the atypical protein kinase C, PKCι. We have previously shown that PKCι is required for glioblastoma cell invasion, primarily by enhancing cell motility. Here we have used time-lapse videomicroscopy to more precisely define the role of PKCι in glioblastoma.


RESULTS
Glioblastoma cells in which PKCι was either depleted by shRNA or inhibited pharmacologically were unable to coordinate the formation of a single leading edge lamellipod. Instead, some cells generated multiple small, short-lived protrusions while others generated a diffuse leading edge that formed around the entire circumference of the cell. Confocal microscopy showed that this behavior was associated with altered behavior of the cytoskeletal protein Lgl, which is known to be inactivated by PKCι phosphorylation. Lgl in control cells localized to the lamellipod leading edge and did not associate with its binding partner non-muscle myosin II, consistent with it being in an inactive state. In PKCι-depleted cells, Lgl was concentrated at multiple sites at the periphery of the cell and remained in association with non-muscle myosin II. Videomicroscopy also identified a novel role for PKCι in the cell cycle. Cells in which PKCι was either depleted by shRNA or inhibited pharmacologically entered mitosis normally, but showed marked delays in completing mitosis.


CONCLUSIONS
PKCι promotes glioblastoma motility by coordinating the formation of a single leading edge lamellipod and has a role in remodeling the cytoskeleton at the lamellipod leading edge, promoting the dissociation of Lgl from non-muscle myosin II. In addition PKCι is required for the transition of glioblastoma cells through mitosis. PKCι therefore has a role in both glioblastoma invasion and proliferation, two key aspects in the malignant nature of this disease.
Baldwin
R Mitchell
RM
Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa K1H 8L6, Canada.
Barrett
Gordon M
GM
Parolin
Doris A E
DA
Gillies
Jana K
JK
Paget
Judith A
JA
Lavictoire
Sylvie J
SJ
Gray
Douglas A
DA
Lorimer
Ian A J
IA
D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects / Q000235:genetics; D003598:Cytoskeletal Proteins / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005455:Fluorescent Antibody Technique; D005909:Glioblastoma / Q000201:enzymology* / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D018613:Microscopy, Confocal; D018715:Microscopy, Video; D024462:Myosin Type II / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D059008:Time-Lapse Imaging; D000099293:Protein Kinase C-lambda
D003598:Cytoskeletal Proteins; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D024462:Myosin Type II; D011493:Protein Kinase C; D034741:RNA, Small Interfering; D000099293:Protein Kinase C-lambda
Cancer Res. 2010 Mar 1;70(5):2064-74
20179210
Nat Cell Biol. 2000 Aug;2(8):531-9
10934474
Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12519-24
16116079
Cell. 2001 Aug 24;106(4):489-98
11525734
J Cell Sci. 2006 Mar 15;119(Pt 6):979-87
16525119
Nature. 2003 Mar 20;422(6929):326-30
12629552
EMBO J. 1996 Feb 15;15(4):788-98
8631300
Nat Cell Biol. 2007 Mar;9(3):299-309
17310241
Nat Cell Biol. 2003 Apr;5(4):301-8
12629547
Cell Mol Life Sci. 2007 Feb;64(4):458-78
17260089
Bioessays. 2003 Jun;25(6):542-53
12766944
Pharmacol Res. 2007 Jun;55(6):487-97
17570678
J Biol Chem. 2006 Feb 17;281(7):4457-66
16361262
Cancer Res. 2006 May 1;66(9):4627-35
16651413
Curr Biol. 2005 Feb 8;15(3):276-82
15694314
Oncogene. 2006 May 11;25(20):2909-19
16331246
Int J Cancer. 2005 Dec 20;117(6):905-12
15986432
Cancer Res. 2005 Oct 1;65(19):8905-11
16204062
Cancer Res. 1999 Jan 15;59(2):442-9
9927060
J Immunol Methods. 2000 Apr 3;237(1-2):147-57
10725459
Science. 2000 Jul 7;289(5476):113-6
10884224
Genes Dev. 2004 Mar 1;18(5):559-71
15037549
Neuropathology. 2005 Mar;25(1):1-7
15822813
Oncogene. 1995 Jul 20;11(2):291-301
7542763
Cell. 2008 Oct 3;135(1):161-73
18854163
Oncogene. 2008 Jun 5;27(25):3587-95
18212741
J Cell Sci. 2007 Sep 1;120(Pt 17):2987-96
17715155
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
J Cell Biol. 2004 Jan 19;164(2):279-90
14734537
Science. 1998 Sep 25;281(5385):2042-5
9748166